Christian Angermayer on ATAI’s Breakthrough Year — FDA Recognition and the Future of Mental Health скачать в хорошем качестве

Christian Angermayer on ATAI’s Breakthrough Year — FDA Recognition and the Future of Mental Health

Psychedelic medicine is entering a breakthrough phase — and few investors have been earlier or more influential than Christian Angermayer. In this #AlphaNooner, we’ll cover why the sector is gaining real traction, what’s driving renewed institutional interest, and how $ATAI is advancing with promising new data from its BPL-003 depression study, recent FDA Breakthrough Therapy Designation, and its runway heading into Phase 3. Essential viewing for investors watching the next frontier in mental-health treatment. Tune in for the AlphaNooner, Daily at 12:00 pm ET Each weekday at 12:00 pm ET, join us live for the AdvisorShares AlphaNooner show (#alphanooner) where we discuss timely topics with experts. We want you to join the conversation! Live questions are welcome from X, YouTube, LinkedIn, and Facebook. Follow Us → YouTube: @advisorshares X: @advisorshares LinkedIn: @advisorshares Instagram: @advisorshares Facebook: @advisorshares